CITR CitroTech Inc.
Chemicals & Allied Products · NYSE · SEC CIK 894556 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.3%
TTM net income YoY43.2%
TTM EPS YoY78.7%
Revenue 3-yr CAGR87.7%
Net income 3-yr CAGR—
Margins
Gross margin23.6%
Operating margin-927.5%
Net margin-1,071.4%
FCF margin-447.2%
EBITDA margin-901.0%
Returns
ROE-235.3%
ROA-177.7%
ROIC (approx.)-293.9%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets15.7%
Debt / equity0.00x
Current ratio2.99x
Interest coverage-44.68x
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-103.5%
Payout ratio—
Capex / revenue-0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.38M | $808,372 |
| Cost of revenue | $1.85M | $655,499 |
| Gross profit | $530,725 | $152,873 |
| R&D expense | $198,505 | $14,002 |
| SG&A expense | $1.59M | $498,445 |
| Operating income | -$16.50M | -$5.30M |
| Interest expense | $1.51M | $257,782 |
| Pretax income | -$36.84M | -$6.88M |
| Income tax | $0 | $0 |
| Net income | -$36.84M | -$6.88M |
| EBITDA | -$16.17M | -$5.04M |
| EPS (basic) | -2.96 | -0.82 |
| EPS (diluted) | -2.96 | -0.82 |
| Weighted avg. shares (diluted) | 12.44M | 8.38M |
| Balance sheet | ||
| Cash & equivalents | $6.27M | $775,133 |
| Receivables | $209,047 | $317,455 |
| Inventory | $620,768 | $324,657 |
| Current assets | $7.42M | $1.62M |
| PP&E, net | $630,279 | $111,374 |
| Intangibles | $5.33M | $3.70M |
| Total assets | $14.18M | $5.48M |
| Current liabilities | $2.17M | $2.16M |
| Short-term debt | — | $96,849 |
| Long-term debt | — | $0 |
| Total debt | — | $96,849 |
| Total liabilities | $2.92M | $2.16M |
| Shareholders' equity | $11.26M | $3.32M |
| Net debt | — | -$678,284 |
| Shares outstanding | 18.52M | 6.14M |
| Cash flow statement | ||
| Operating cash flow | -$5.87M | -$1.94M |
| Capital expenditure | $193,953 | $0 |
| Free cash flow | -$6.06M | -$1.94M |
| Investing cash flow | -$293,953 | $0 |
| Financing cash flow | $11.66M | $2.16M |
| Depreciation & amortization | $329,334 | $264,696 |
| Stock-based compensation | $19.14M | $3.06M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.